Kb111
Phase 1
Kb111 is one of 3 therapeutic programs targeting Hailey-Hailey disease. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
2 competitors in Hailey-Hailey Disease
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonPhase 2
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Kb111
KKrystal Biotech, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Kb111. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- KKrystal Biotech, Inc.